KEYNOTE-590 Archives - Medical Conferences

KEYNOTE-590: 5-Year outcomes confirm benefit of pembrolizumab in oesophageal cancer

Presented By

Prof. Manish Shah, Weill Cornell Medicine, NY, USA

Trial

Phase 3, KEYNOTE-590

Conference

ASCO GI 2024

Type

News article

13 February 2024 14:26

Presented By

Dr Jean-Philippe Metges, CHU Brest, France; Dr Zev Wainberg, University College Los Angeles, CA, USA

Trial

Phase 3, KEYNOTE-590, KEYNOTE-062

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 11:08

Presented By

Dr Rachel Giles, Medicom

Conference

ASCO GI 2022

8 February 2022 12:37